Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum

Laboratory investigation

Restricted access

Object

Although several clinical trials utilizing the adeno-associated virus (AAV) type 2 serotype 2 (2/2) are now underway, it is unclear whether this particular serotype offers any advantage over others in terms of safety or efficiency when delivered directly to the CNS.

Methods

Recombinant AAV2–green fluorescent protein (GFP) serotypes 2/1, 2/2, 2/5, and 2/8 were generated following standard triple transfection protocols (final yield 5.4 × 1012 particles/ml). A total of 180 μl of each solution was stereotactically infused, covering the entire rostrocaudal extent of the caudoputamen in 4 rhesus monkeys (Macaca mulatta) (3.0 ± 0.5 kg). After 6 weeks' survival, the brain was formalin fixed, cut at 40 μm, and stained with standard immunohistochemistry for anti-GFP, anticaspase-2, and cell-specific markers (anti–microtubule-associated protein-2 for neurons and anti–glial fibrillary acidic protein for glia). Unbiased stereological counting methods were used to determine cell number and striatal volume.

Results

The entire striatum of each animal contained GFP-positive cells with significant labeling extending beyond the borders of the basal ganglia. No ischemic/necrotic, hemorrhagic, or neoplastic change was observed in any brain. Total infusate volumes were similar across the 4 serotypes. However, GFP-labeled cell density was markedly different. Adeno-associated virus 2/1, 2/2, and 2/5 each labeled < 8000 cells/mm3, whereas serotype 8 labeled > 21,000 cells, a 3- to 4-fold higher transduction efficiency. On the other hand, serotype 8 also labeled neurons and glia with equal affinity compared with neuronal specificities > 89% for the other serotypes. Moderate caspase-2 colabeling was noted in neurons immediately around the AAV2/1 injection tracts, but was not seen above the background anywhere in the brain following injections with serotypes 2, 5, or 8.

Conclusions

Intrastriatal delivery of AAV2 yields the highest cell transduction efficiencies but lowest neuronal specificity for serotype 8 when compared with serotypes 1, 2, and 5. Only AAV2/1 revealed significant caspase-2 activation. Careful consideration of serotype-specific differences in AAV2 neurotropism, transduction efficiency, and potential toxicity may affect future human trials.

Abbreviations used in this paper: AAV2 = adeno-associated virus type 2; AAV2/2 = AAV2 serotype 2; CBA = CMV/chicken β-actin; CED = convection-enhanced delivery; CMV = cytomegalovirus; EGFP = enhanced green fluorescent protein; GFAP = glial fibrillary acidic protein; GFP = green fluorescent protein; hrGFP = humanized Renilla reniformis GFP; MAP = microtubule-associated protein; PBS = phosphate-buffered saline; TK = thymidine kinase.

Article Information

* Drs. Sanchez and Tierney contributed equally to this work.

Address correspondence to: Bob S. Carter, M.D., Ph.D., Department of Neurosurgery, University of California, San Diego, 200 West Arbor Drive, Mail Code 8893, San Diego, California 92103. email: bobcarter@ucsd.edu.

Please include this information when citing this paper: published online October 15, 2010; DOI: 10.3171/2010.8.JNS091583.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Transduction of nonhuman primate striatum by recombinant AAV2/2. Sections were double-stained for neuronal-specific nuclear protein (NeuN-neurons) and EGFP (AAV-transgene). A: Brightfield low-power mosaic image of striatum. Original magnification × 100. B–E: Windows of fluorescence GFP staining. Original magnification × 10. F: Low-power fluorescence mosaic image with GFP and 4,6′-diamino-2-phenylindole-dihydrochloride (DAPI) demonstrating high transduction efficiency at the border between the caudate and internal capsule. Original magnification × 10. G: GFP, NeuN, and combined GFP and NeuN fluorescence images with DAPI showing high transduction efficiency in GFP window, high neuronal density in NeuN window, and complete overlap in GFP and NeuN combined window with the recombinant AAV2/2 construct. Original magnification × 4 (lower row), × 20 (upper row). Cd = caudate; GPe = globus pallidus externus; GPi = globus pallidus internus; Ic = internal capsule; Pu = putamen.

  • View in gallery

    Graphs showing number of GFP positively labeled cells (A), transduction efficiency (B), cell type specificity (C), and estimated transduction number of neurons and glia (D), using unbiased stereological counts. A: Number of positively labeled cells in striatum with single-sided injection, in which AAV2/8 > AAV2/5 > AAV2/2 > AAV2/1. B: Transduction efficiency (number of GFP-positive cells/mm3), in which AAV2/8 > AAV2/5 > AAV2/2 > AAV2/1. C: Cell type specificity (percentage of labeled cells) demonstrating almost complete neuronal specificity with AAV2/1, AAV2/2, and AAV2/5, but mixed cell type specificity with AAV2/8. D: Cell type specificity applied to stereological results from panel A, for estimated total number of transduced neurons and glia in striatum.

  • View in gallery

    Serotype-specific transduction differences between recombinant AAV2/1, 2/2, 2/5, and 2/8. Triple-labeled confocal micrographs with merged images (larger images) and single channels (smaller images) in GFP, MAP2 (neurons), and GFAP (glia). Adeno-associated virus 2/1, 2/2, and 2/5 show predominantly neuronal colabeling of MAP2 and GFP, whereas AAV2/8 demonstrates an almost equal combination of GFAP and MAP2 with GFP. Counts from confocal images were used to generate cell type specificity measurements. Bar = 100 μm.

  • View in gallery

    Caspase-3 activation near the injection tract of AAV2/1. Green fluorescent protein, caspase-3, and DAPI fluorescence images near (A–C) and away from (D–F) injection tract. Caspase-3 activation noted surrounding and around the injection tract (B) of AAV2/1, but not noted with other serotypes. Caspase-3 activation not observed beyond the needle tract (E) in any serotype.

References

1

Bankiewicz KSEberling JLKohutnicka MJagust WPivirotto PBringas J: Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164:2142000

2

Bankiewicz KSForsayeth JEberling JLSanchez-Pernaute RPivirotto PBringas J: Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14:5645702006

3

Bobo RHLaske DWAkbasak AMorrison PFDedrick RLOldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:207620801994

4

Broekman MLComer LAHyman BTSena-Esteves M: Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 138:5015102006

5

Burger CGorbatyuk OSVelardo MJPeden CSWilliams PZolotukhin S: Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:3023172004

6

Cunningham JPivirotto PBringas JSuzuki BVijay SSanftner L: Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther 16:126712752008

7

Eberling JLJagust WJChristine CWStarr PLarson PBankiewicz KS: Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70:198019832008

8

Emborg MECarbon MHolden JEDuring MJMa YTang C: Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 27:5015092007

9

Forsayeth JREberling JLSanftner LMZhen ZPivirotto PBringas J: A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther 14:5715772006

10

Gao GPAlvira MRWang LCalcedo RJohnston JWilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99:11854118592002

11

Hadaczek PForsayeth JMirek HMunson KBringas JPivirotto P: Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther 20:2252372009

12

Hadaczek PKohutnicka MKrauze MTBringas JPivirotto PCunningham J: Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 17:2913022006

13

Hamilton JFMorrison PFChen MYHarvey-White JPernaute RSPhillips H: Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp Neurol 168:1551612001

14

Harding TCDickinson PJRoberts BNYendluri SGonzalez-Edick MLecouteur RA: Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors. Hum Gene Ther 17:8078202006

15

Hildinger MAuricchio AGao GWang LChirmule NWilson JM: Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 75:619962032001

16

Kaplitt MGFeigin ATang CFitzsimons HLMattis PLawlor PA: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369:209721052007

17

Kells APHadaczek PYin DBringas JVarenika VForsayeth J: Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A 106:240724112009

18

Klein RLDayton RDLeidenheimer NJJansen KGolde TEZweig RM: Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther 13:5175272006

19

Klein RLDayton RDTatom JBHenderson KMHenning PP: AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol Ther 16:89962008

20

Lawlor PABland RJMouravlev AYoung DDuring MJ: Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17:169217022009

21

Lieberman DMLaske DWMorrison PFBankiewicz KSOldfield EH: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82:102110291995

22

Mandel RJManfredsson FPFoust KDRising AReimsnider SNash K: Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 13:4634832006

23

Marks WJ JrOstrem JLVerhagen LStarr PALarson PSBakay RA: Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7:4004082008

24

McBride JLBoudreau RLHarper SQStaber PDMonteys AMMartins I: Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A 105:586858732008

25

McFarland NRLee JSHyman BTMcLean PJ: Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. J Neurochem 109:8388452009

26

McPhee SWJanson CGLi CSamulski RJCamp ASFrancis J: Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 8:5775882006

27

Passini MAWatson DJWolfe JH: Gene delivery to the mouse brain with adeno-associated virus. Methods Mol Biol 246:2252362004

28

Paterna JCFeldon JBüeler H: Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. J Virol 78:680868172004

29

Paxinos GHaung XFPetrides MToga AW: The Rhesus Monkey Brain in Stereotaxic Coordinates ed. 2San DiegoAcademic Press2008

30

Rabinowitz JERolling FLi CConrath HXiao WXiao X: Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76:7918012002

31

Reimsnider SManfredsson FPMuzyczka NMandel RJ: Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 15:150415112007

32

Sanchez CEGale JTierney TSMulligan RCCarter BS: AAV2-mediated gene delivery to the non-human primate striatum: development of a multi-catheter injection system for reproducible single-measure intraoperative convection enhanced delivery. Presented at the Annual Meeting of the Congress of Neurological SurgeonsOrlando, FloridaSeptember 20–25, 2008(Poster) (http://2008.cns.org/posterbrowser.aspx) [Accessed August 24 2010]

33

Sands MSDavidson BL: Gene therapy for lysosomal storage diseases. Mol Ther 13:8398492006

34

Taymans JMVandenberghe LHHaute CVThiry IDeroose CMMortelmans L: Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 18:1952062007

35

Tierney TSPradilla GWang PPClatterbuck RETamargo RJ: Intracranial delivery of the nitric oxide donor diethylenetriamine/ nitric oxide from a controlled-release polymer: toxicity in cynomolgus monkeys. Neurosurgery 58:9529602006

36

West MJSlomianka LGundersen HJ: Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:4824971991

37

Worgall SSondhi DHackett NRKosofsky BKekatpure MVNeyzi N: Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adenoassociated virus expressing CLN2 cDNA. Hum Gene Ther 19:4634742008

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 99 99 29
Full Text Views 112 112 11
PDF Downloads 107 107 10
EPUB Downloads 0 0 0

PubMed

Google Scholar